Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
X
Announcing new Tapestri Platform updates including lowered input threshold and expanded heme-onc menu. Learn More
X
publication

Personalized single-cell proteogenomics to distinguish acute myeloid leukemia from nonmalignant clonal hematopoiesis


Dillon, L.W. et al.
Blood Cancer Discovery (2021)
Abstract

Genetic mutations associated with acute myeloid leukemia (AML) also occur in agerelated clonal hematopoiesis, often in the same individual. This makes confident assignment of detected variants to malignancy challenging. The issue is particularly crucial for AML posttreatment measurable residual disease monitoring, where results can be discordant between genetic sequencing and flow cytometry. We show here that it is possible to distinguish AML from clonal hematopoiesis and to resolve the immunophenotypic identity of clonal architecture. To achieve this, we first design patient-specific DNA probes based on patient’s whole-genome sequencing and then use them for patient-personalized single-cell DNA sequencing with simultaneous single-cell antibody–oligonucleotide sequencing. Examples illustrate AML arising from DNMT3A- and TET2-mutated clones as well as independently. The ability to personalize single-cell proteogenomic assessment for individual patients based on leukemia-specific genomic features has implications for ongoing AML precision medicine efforts.



Authors

Dillon, L.W., Ghannam, J., Nosiri, C., Gui, G., Goswami, M., Calvo, K.R., Lindblad, K.E., Oetjen, K.A., Wilkerson, M., Soltis, A.R., Sukumar, G., Dalgard, C.L., Thompson, J., Valdez, J., DeStefano, C.B., Lai1, C., Sciambi, A., Durruthy-Durruthy, R., Llanso, A, Gulati, S, Wang, S., Ooi, A., Dagur, P.K., McCoy, J.P., Burr, P., Li, Y., Hourigan, C.S.



VIEW

publication
Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma
Marin-Bejar, O.
Cancer Cell (2021)
publication
Intact TP-53 function is essential for sustaining durable responses to BH3-mimetic drugs in leukemias
Thijssen, R.
Blood (2021)
publication
PIK3CA and CCM mutations fuel cavernomas through a cancer-like mechanism
Ren, A.A.
Nature (2021)
publication
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia
Wang, F.
Nature Communications (2021)
REQUEST QUOTE